Mutational signatures among young-onset testicular cancers

BMC Medical Genomics

Table 2 Types of nucleotide alterations

Gene	20–29	30–39	> 40	p-value (20–29 vs. > 40)	p-value (30–39 vs. > 40)	p-value (continuous age)
C > A	1510 (21%)	1268 (21%)	582 (18%)	0.085	0.10	0.18
C > G	896 (12%)	742 (12%)	460 (15%)	0.15	0.22	0.18
C > T	2712 (37%)	2220 (37%)	1120 (36%)	0.94	0.76	0.80
T > A	566 (8%)	440 (7%)	240 (8%)	0.79	0.86	0.79
T > C	1182 (16%)	986 (16%)	518 (16%)	0.64	0.82	0.90
T > G	494 (7%)	352 (6%)	228 (7%)	0.54	0.12	0.82

Prevalence of somatic nucleotide alterations among testicular tumors diagnosed at ages 20–29 (n = 59), 30–39 (n = 54), and age 40 or older (n = 21). Entries are number (proportion) of mutations type in each age of onset group. Differences in types of nucleotide laterations by age at onset groups were tested using a logistic regression model * indicates statistical significance at a .05 level

ISSN: 1755-8794